Home
Clinical Resources Search
PQI: Sotorasib (Lumakras®) Companion Diagnostics (QIAGEN therascreen® KRAS RGQ PCR Kit and Guardant360® CDx)

Sotorasib (Lumakras®) Companion Diagnostics (QIAGEN therascreen® KRAS RGQ PCR Kit and Guardant360® CDx)

Download PQI pdf 0.11MB

Last Updated: November 29, 2023

By: Porscha Johnson, PharmD, CPGx

About this PQI

Sotorasib (Lumakras®) is a first-in-class oral medication FDA-approved for the treatment of adult patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. In order to be assessed for drug eligibility, a patient’s KRAS G12C positive status must first be determined by an FDA-approved companion diagnostics test including QIAGEN therascreen® KRAS RGQ PCR Kit or Guardant360® CDx prior to therapy initiation.1,2

More About This PQI

PQI:

Sotorasib-Lumakras®-for-KRAS-G12C-mutated-Non-Small-Cell-Lung-Cancer-NSCLC_PQI_NCODA pdf 0.12MB

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Genomics Non-Small Cell Lung Cancer (NSCLC) Guardant360 Lumakras QIAGEN Sotorasib

PQI

PQI: Ibrutinib Dosing Optimization

Author: Nick Bouchard, PharmD | Danielle Maciorowski, PharmD

Frequently Searched

Supported by

Sotorasib (Lumakras®) Companion Diagnostics (QIAGEN therascreen® KRAS RGQ PCR Kit and Guardant360® CDx)

About this PQI

More About This PQI

PQI:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Ibrutinib Dosing Optimization

PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management

PQI: Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PQI: Vorasidenib (Voranigo®)

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease

PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings

The PQI Podcast S3 Ep 13: The Importance of the Multidisciplinary Team

Readiness Tracker

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Treatment Support Kit: Tivozanib

Treatment Support Kit: Regorafenib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

PQI: Selpercatinib (Retevmo®) Genomic Testing Management

PQI Podcast S6 Ep 2: Molecular Testing & Targeted Treatment in Colorectal Cancer

PQI Podcast S6 Ep 9: ctDNA Testing in GI Cancers

PQI Podcast S7 Ep 12: Advancing Cancer Care with Precision Medicine & the Pharmacist’s Role

PQI: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancer with MET Exon 14 Alterations

PQI: Sotorasib (Lumakras®) for KRAS G12C-mutated Non-Small Cell Lung Cancer (NSCLC)

PQI: Selpercatinib (Retevmo®) Management

PQI: Selpercatinib (Retevmo®) Genomic Testing Management

PQI: Sotorasib (Lumakras®) for KRAS G12C-mutated Non-Small Cell Lung Cancer (NSCLC)

PQI: Sotorasib (Lumakras®) for KRAS G12C-mutated Non-Small Cell Lung Cancer (NSCLC)

PQI: Sotorasib (Lumakras®) for KRAS G12C-mutated Non-Small Cell Lung Cancer (NSCLC)

PQI: Sotorasib (Lumakras®) for KRAS G12C-mutated Non-Small Cell Lung Cancer (NSCLC)

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings